Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224129 | 0.87 | LMNA (0.49) | LMNAGAATSHRKMT2AHPGD | |
| SCHEMBL2222205 | 0.83 | LMNA (0.59) | LMNAGAATSHRKMT2AHPGD | |
| SCHEMBL27787138 | 0.80 | LMNA (0.52) | LMNAGAATSHRKMT2AHPGD | |
| SCHEMBL4271884 | 0.78 | S1PR1 (0.47) | LMNAKMT2AHPGD | |
| SCHEMBL2817919 | 0.76 | LMNA (0.57) | LMNAGAATSHRKMT2AHPGD | |
| SCHEMBL26104287 | 0.76 | SMN1; SMN2 (0.42) | LMNAHDAC1HDAC8HDAC6CYP11B1 | |
| SCHEMBL12445017 | 0.76 | LMNA (0.49) | LMNAGAATSHRKMT2AHPGD | |
| SCHEMBL4277046 | 0.76 | PPARG (0.42) | LMNAGAATSHRKMT2AHPGD | |
| SCHEMBL5855718 | 0.75 | LMNA (0.45) | LMNAGAATSHRKMT2AHPGD | |
| SCHEMBL5855890 | 0.75 | LMNA (0.45) | LMNAGAATSHRKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| EP-2523560-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | LMNA 28/4885GAA 1423/4885TSHR 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.